Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Steroid sulfatase inhibiting lanostane triterpenes - Structure activity relationship and in silico insights.

Grienke U, Kaserer T, Kirchweger B, Lambrinidis G, Kandel RT, Foster PA, Schuster D, Mikros E, Rollinger JM.

Bioorg Chem. 2019 Dec 9;95:103495. doi: 10.1016/j.bioorg.2019.103495. [Epub ahead of print]

PMID:
31855822
2.

Synthesis and in vitro evaluation of piperazinyl-ureido sulfamates as steroid sulfatase inhibitors.

Moi D, Foster PA, Rimmer LG, Jaffri A, Deplano A, Balboni G, Onnis V, Potter BVL.

Eur J Med Chem. 2019 Nov 15;182:111614. doi: 10.1016/j.ejmech.2019.111614. Epub 2019 Aug 12.

PMID:
31422224
3.

1H NMR-MS-based heterocovariance as a drug discovery tool for fishing bioactive compounds out of a complex mixture of structural analogues.

Grienke U, Foster PA, Zwirchmayr J, Tahir A, Rollinger JM, Mikros E.

Sci Rep. 2019 Jul 31;9(1):11113. doi: 10.1038/s41598-019-47434-8.

4.

Steroid sulfation research has come a long way.

Mueller JW, Foster PA.

J Mol Endocrinol. 2018 Aug;61(2):E5-E6. doi: 10.1530/JME-18-0109. No abstract available.

PMID:
30030389
5.

Nicotinamide Nucleotide Transhydrogenase as a Novel Treatment Target in Adrenocortical Carcinoma.

Chortis V, Taylor AE, Doig CL, Walsh MD, Meimaridou E, Jenkinson C, Rodriguez-Blanco G, Ronchi CL, Jafri A, Metherell LA, Hebenstreit D, Dunn WB, Arlt W, Foster PA.

Endocrinology. 2018 Aug 1;159(8):2836-2849. doi: 10.1210/en.2018-00014.

6.

SULFATION PATHWAYS: Insights into steroid sulfation and desulfation pathways.

Foster PA, Mueller JW.

J Mol Endocrinol. 2018 Aug;61(2):T271-T283. doi: 10.1530/JME-18-0086. Epub 2018 May 15. Review.

PMID:
29764919
7.

SULFATION PATHWAYS: A role for steroid sulphatase in intracrine regulation of endometrial decidualisation.

Gibson DA, Foster PA, Simitsidellis I, Critchley HOD, Kelepouri O, Collins F, Saunders PTK.

J Mol Endocrinol. 2018 Aug;61(2):M57-M65. doi: 10.1530/JME-18-0037. Epub 2018 May 2. Review.

8.

Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure.

Dohle W, Jourdan FL, Menchon G, Prota AE, Foster PA, Mannion P, Hamel E, Thomas MP, Kasprzyk PG, Ferrandis E, Steinmetz MO, Leese MP, Potter BVL.

J Med Chem. 2018 Feb 8;61(3):1031-1044. doi: 10.1021/acs.jmedchem.7b01474. Epub 2018 Jan 8.

PMID:
29227648
9.

NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice.

Meimaridou E, Goldsworthy M, Chortis V, Fragouli E, Foster PA, Arlt W, Cox R, Metherell LA.

J Endocrinol. 2018 Jan;236(1):13-28. doi: 10.1530/JOE-16-0638. Epub 2017 Oct 18.

10.

Estrogen Activation by Steroid Sulfatase Increases Colorectal Cancer Proliferation via GPER.

Gilligan LC, Rahman HP, Hewitt AM, Sitch AJ, Gondal A, Arvaniti A, Taylor AE, Read ML, Morton DG, Foster PA.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4435-4447. doi: 10.1210/jc.2016-3716.

11.

Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy.

Gilligan LC, Gondal A, Tang V, Hussain MT, Arvaniti A, Hewitt AM, Foster PA.

Front Pharmacol. 2017 Mar 7;8:103. doi: 10.3389/fphar.2017.00103. eCollection 2017.

12.

In touch with your feminine side: how oestrogen metabolism impacts prostate cancer.

Rahman HP, Hofland J, Foster PA.

Endocr Relat Cancer. 2016 Jun;23(6):R249-66. doi: 10.1530/ERC-16-0118. Epub 2016 May 18. Review.

PMID:
27194038
13.

Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors.

El-Gamal MI, Semreen MH, Foster PA, Potter BV.

Bioorg Med Chem. 2016 Jun 15;24(12):2762-7. doi: 10.1016/j.bmc.2016.04.040. Epub 2016 Apr 22.

14.

The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression.

Stengel C, Newman SP, Leese MP, Thomas MP, Potter BV, Reed MJ, Purohit A, Foster PA.

Anticancer Res. 2015 Oct;35(10):5249-61.

15.

The Regulation of Steroid Action by Sulfation and Desulfation.

Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA.

Endocr Rev. 2015 Oct;36(5):526-63. doi: 10.1210/er.2015-1036. Epub 2015 Jul 27. Review.

16.

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL.

Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC.

Blood. 2014 Dec 4;124(24):3553-60. doi: 10.1182/blood-2014-08-593269. Epub 2014 Oct 9.

17.

A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma.

Kumar A, Blum KA, Fung HC, Smith MR, Foster PA, Younes A.

Br J Haematol. 2015 Mar;168(6):902-4. doi: 10.1111/bjh.13152. Epub 2014 Oct 1. No abstract available.

PMID:
25271537
18.

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer.

Stengel C, Newman SP, Day JM, Chander SK, Jourdan FL, Leese MP, Ferrandis E, Regis-Lydi S, Potter BV, Reed MJ, Purohit A, Foster PA.

Br J Cancer. 2014 Jul 15;111(2):300-8. doi: 10.1038/bjc.2014.188. Epub 2014 Jun 24.

19.

STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.

Meyer-Losic F, Newman SP, Day JM, Reed MJ, Kasprzyk PG, Purohit A, Foster PA.

PLoS One. 2013 Dec 6;8(12):e80305. doi: 10.1371/journal.pone.0080305. eCollection 2013.

20.

Oestrogen and colorectal cancer: mechanisms and controversies.

Foster PA.

Int J Colorectal Dis. 2013 Jun;28(6):737-49. doi: 10.1007/s00384-012-1628-y. Epub 2013 Jan 15. Review.

PMID:
23319136
21.

The treatment of complex tibial shaft fractures by the Ilizarov method.

Foster PA, Barton SB, Jones SC, Morrison RJ, Britten S.

J Bone Joint Surg Br. 2012 Dec;94(12):1678-83. doi: 10.1302/0301-620X.94B12.29266.

PMID:
23188911
22.

STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.

Day JM, Foster PA, Tutill HJ, Schmidlin F, Sharland CM, Hargrave JD, Vicker N, Potter BV, Reed MJ, Purohit A.

Endocr Relat Cancer. 2013 Feb 18;20(1):53-64. doi: 10.1530/ERC-12-0231. Print 2013 Feb.

PMID:
23132791
23.

Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers.

Purohit A, Foster PA.

J Endocrinol. 2012 Feb;212(2):99-110. doi: 10.1530/JOE-11-0266. Epub 2011 Aug 22. Review.

PMID:
21859802
24.

Chimeric microtubule disruptors.

Leese MP, Jourdan F, Kimberley MR, Cozier GE, Thiyagarajan N, Stengel C, Regis-Lydi S, Foster PA, Newman SP, Acharya KR, Ferrandis E, Purohit A, Reed MJ, Potter BV.

Chem Commun (Camb). 2010 May 7;46(17):2907-9. doi: 10.1039/c002558e. Epub 2010 Mar 20.

PMID:
20386818
25.

Monitoring of oxygen condition in the Ria Formosa coastal lagoon, Portugal.

Newton A, Oliveira PS, Icely JD, Foster PA.

J Environ Monit. 2010 Jan;12(1):355-60. doi: 10.1039/b914015h. Epub 2009 Nov 25.

PMID:
20082032
26.

Pressures available for transtracheal jet ventilation from anesthesia machines and wall-mounted oxygen flowmeters.

Fassl J, Jenny U, Nikiforov S, Murray WB, Foster PA.

Anesth Analg. 2010 Jan 1;110(1):94-100. doi: 10.1213/ANE.0b013e3181c22021. Epub 2009 Nov 12.

PMID:
19910614
27.

STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells.

Foster PA, Ho YT, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A.

Anticancer Res. 2009 Oct;29(10):3751-7.

28.

The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy.

Day JM, Purohit A, Tutill HJ, Foster PA, Woo LW, Potter BV, Reed MJ.

Ann N Y Acad Sci. 2009 Feb;1155:80-7. doi: 10.1111/j.1749-6632.2008.03677.x. Review.

PMID:
19250195
29.

BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

Day JM, Foster PA, Tutill HJ, Newman SP, Ho YT, Leese MP, Potter BV, Reed MJ, Purohit A.

Br J Cancer. 2009 Feb 10;100(3):476-86. doi: 10.1038/sj.bjc.6604873. Epub 2009 Jan 20.

30.

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer.

Tagg SL, Foster PA, Leese MP, Potter BV, Reed MJ, Purohit A, Newman SP.

Br J Cancer. 2008 Dec 2;99(11):1842-8. doi: 10.1038/sj.bjc.6604752. Epub 2008 Nov 4.

31.

A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.

Foster PA, Chander SK, Newman SP, Woo LW, Sutcliffe OB, Bubert C, Zhou D, Chen S, Potter BV, Reed MJ, Purohit A.

Clin Cancer Res. 2008 Oct 15;14(20):6469-77. doi: 10.1158/1078-0432.CCR-08-1027.

32.

Recent developments of steroid sulfatase inhibitors as anti-cancer agents.

Foster PA, Reed MJ, Purohit A.

Anticancer Agents Med Chem. 2008 Oct;8(7):732-8. Review.

PMID:
18855575
33.

The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.

Parsons MF, Foster PA, Chander SK, Jhalli R, Newman SP, Leese MP, Potter BV, Purohit A, Reed MJ.

Br J Cancer. 2008 Nov 4;99(9):1433-41. doi: 10.1038/sj.bjc.6604707. Epub 2008 Oct 7.

34.

Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.

Day JM, Tutill HJ, Foster PA, Bailey HV, Heaton WB, Sharland CM, Vicker N, Potter BV, Purohit A, Reed MJ.

Mol Cell Endocrinol. 2009 Mar 25;301(1-2):251-8. doi: 10.1016/j.mce.2008.08.014. Epub 2008 Aug 22.

PMID:
18786604
35.

Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography.

Woo LW, Fischer DS, Sharland CM, Trusselle M, Foster PA, Chander SK, Di Fiore A, Supuran CT, De Simone G, Purohit A, Reed MJ, Potter BV.

Mol Cancer Ther. 2008 Aug;7(8):2435-44. doi: 10.1158/1535-7163.MCT-08-0195.

36.

A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140.

Foster PA, Stengel C, Ali T, Leese MP, Potter BV, Reed MJ, Purohit A, Newman SP.

Anticancer Res. 2008 May-Jun;28(3A):1483-91.

37.

A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.

Foster PA, Newman SP, Leese MP, Bernetiere S, Diolez C, Camara J, Hacher B, Baronnet MM, Ali T, Potter BV, Reed MJ, Purohit A.

Anticancer Res. 2008 Mar-Apr;28(2A):577-81.

38.

The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.

Foster PA, Woo LW, Potter BV, Reed MJ, Purohit A.

Endocrinology. 2008 Aug;149(8):4035-42. doi: 10.1210/en.2008-0223. Epub 2008 May 1.

39.

Steroid metabolism in breast cancer.

Foster PA.

Minerva Endocrinol. 2008 Mar;33(1):27-37. Review.

40.

Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.

Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2008 Mar 13;51(5):1295-308. doi: 10.1021/jm701319c. Epub 2008 Feb 9.

PMID:
18260615
41.

STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.

Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde JG, Lassalle M, Prevost G, Leese MP, Potter BV, Reed MJ, Purohit A.

Clin Cancer Res. 2008 Jan 15;14(2):597-606. doi: 10.1158/1078-0432.CCR-07-1717.

42.

17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.

Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, Lawrence HR, Vicker N, Potter BV, Reed MJ, Purohit A.

Int J Cancer. 2008 May 1;122(9):1931-40. doi: 10.1002/ijc.23350.

43.

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers.

Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A.

Br J Cancer. 2007 Dec 17;97(12):1673-82. Epub 2007 Nov 20.

44.

2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique.

Foster PA, Ho YT, Newman SP, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A.

Breast Cancer Res Treat. 2008 Sep;111(2):251-60. Epub 2007 Oct 24.

PMID:
17957467
45.

Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.

Foster PA, Chander SK, Parsons MF, Newman SP, Woo LW, Potter BV, Reed MJ, Purohit A.

Breast Cancer Res Treat. 2008 Sep;111(1):129-38. Epub 2007 Oct 4.

PMID:
17914670
46.

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol.

Chander SK, Foster PA, Leese MP, Newman SP, Potter BV, Purohit A, Reed MJ.

Br J Cancer. 2007 May 7;96(9):1368-76. Epub 2007 Apr 10.

47.

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.

Nutt JE, Foster PA, Mellon JK, Lunec J.

Br J Cancer. 2007 Mar 12;96(5):762-8. Epub 2007 Feb 20.

48.

In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.

Foster PA, Newman SP, Chander SK, Stengel C, Jhalli R, Woo LL, Potter BV, Reed MJ, Purohit A.

Clin Cancer Res. 2006 Sep 15;12(18):5543-9.

49.

Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor.

Foster PA, Costa SK, Poston R, Hoult JR, Brain SD.

FASEB J. 2003 Sep;17(12):1703-5. Epub 2003 Jul 18.

PMID:
12958182
50.

Supplemental Content

Loading ...
Support Center